NOT FOR DISTRIBUTION
Header cover image

Market Cap

AU$322.8m

Last Updated

2021/05/07 08:24 UTC

Data Sources

Company Financials

Executive Summary

Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Incannex Healthcare's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IHL is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: IHL's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Australian stocks.


Market Performance


7 Day Return

-3.2%

IHL

-1.2%

AU Pharmaceuticals

0.3%

AU Market


1 Year Return

498.0%

IHL

5.6%

AU Pharmaceuticals

35.9%

AU Market

Return vs Industry: IHL exceeded the Australian Pharmaceuticals industry which returned 1.8% over the past year.

Return vs Market: IHL exceeded the Australian Market which returned 37.3% over the past year.


Shareholder returns

IHLIndustryMarket
7 Day-3.2%-1.2%0.3%
30 Day41.9%-6.1%1.8%
90 Day74.3%-8.3%2.8%
1 Year498.0%498.0%5.8%5.6%39.9%35.9%
3 Year1,187.5%1,073.1%-41.6%-42.1%30.1%14.7%
5 Yearn/a-31.4%-34.7%60.1%29.9%

Long-Term Price Volatility Vs. Market

How volatile is Incannex Healthcare's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Incannex Healthcare undervalued compared to its fair value and its price relative to the market?

26.88x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IHL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IHL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IHL is unprofitable, so we can't compare its PE Ratio to the XO Pharmaceuticals industry average.

PE vs Market: IHL is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IHL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IHL is overvalued based on its PB Ratio (26.9x) compared to the AU Pharmaceuticals industry average (3.3x).


Future Growth

How is Incannex Healthcare forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

68.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Incannex Healthcare has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Incannex Healthcare performed over the past 5 years?

38.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IHL is currently unprofitable.

Growing Profit Margin: IHL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IHL is unprofitable, but has reduced losses over the past 5 years at a rate of 38% per year.

Accelerating Growth: Unable to compare IHL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IHL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.5%).


Return on Equity

High ROE: IHL has a negative Return on Equity (-41.46%), as it is currently unprofitable.


Financial Health

How is Incannex Healthcare's financial position?


Financial Position Analysis

Short Term Liabilities: IHL's short term assets (A$12.2M) exceed its short term liabilities (A$378.4K).

Long Term Liabilities: IHL has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: IHL is debt free.

Reducing Debt: IHL had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IHL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: IHL has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 21% each year.


Dividend

What is Incannex Healthcare current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IHL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IHL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IHL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IHL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IHL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.9yrs

Average management tenure


CEO

Joel Latham

2.92yrs

Tenure

AU$390,380

Compensation

Mr. Joel Bradley Latham has been Chief Executive Officer at Incannex Healthcare Limited (also known as Impression Healthcare Ltd.) since June 29, 2018 and has been its Managing Director and Executive Direc...


CEO Compensation Analysis

Compensation vs Market: Joel's total compensation ($USD303.47K) is below average for companies of similar size in the Australian market ($USD496.94K).

Compensation vs Earnings: Joel's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: IHL's management team is considered experienced (2.9 years average tenure).


Board Members

Experienced Board: IHL's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 45.1%.


Top Shareholders

Company Information

Incannex Healthcare Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Incannex Healthcare Limited
  • Ticker: IHL
  • Exchange: ASX
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$322.839m
  • Shares outstanding: 1.06b
  • Website: https://www.incannex.com.au

Location

  • Incannex Healthcare Limited
  • Rialto South Tower
  • Level 39
  • Melbourne
  • Victoria
  • 3000
  • Australia

Listings


Biography

Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name....


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/07 08:24
End of Day Share Price2021/05/07 00:00
Earnings2020/12/31
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.